Rodriguez E, et al.. Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome? Clin Kidney J 2017; 10:320–322. doi: 10.1093/ckj/sfx024

• Crossref
Rodriguez E, . Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome? Clin Kidney J 2017; 10:320–322. doi: 10.1093/ckj/sfx02410.1093/ckj/sfx024)| false
• Search Google Scholar
• Export Citation

Skoczynska M, et al.. Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: Case report and systematic review of the literature. Lupus 2020; 29:631–639. doi: 10.1177/0961203320917460

• Crossref
Skoczynska M, . Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: Case report and systematic review of the literature. Lupus 2020; 29:631–639. doi: 10.1177/096120332091746010.1177/0961203320917460)| false
• Search Google Scholar
• Export Citation

Nakamura H, et al.. Atypical hemolytic uremic syndrome associated with complement factor H mutation and IgA nephropathy: A case report successfully treated with eculizumab. Nephron 2018; 138:324–327. doi: 10.1159/000485194

• Crossref
Nakamura H, . Atypical hemolytic uremic syndrome associated with complement factor H mutation and IgA nephropathy: A case report successfully treated with eculizumab. Nephron 2018; 138:324–327. doi: 10.1159/00048519410.1159/000485194)| false
• Search Google Scholar
• Export Citation

Palomo M, et al.. Complement activation and thrombotic microangiopathies. Clin J Am Soc Nephrol 2019; 14:1719–1732. doi: 10.2215/CJN.05830519

• Crossref
Palomo M, . Complement activation and thrombotic microangiopathies. Clin J Am Soc Nephrol 2019; 14:1719–1732. doi: 10.2215/CJN.0583051910.2215/CJN.05830519)| false
• Search Google Scholar
• Export Citation

Ariceta G, et al.. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int [published online ahead of print December 8, 2020]. doi: 10.1016/j.kint.2020.10.046; https://www.kidney-international.org/article/S0085-2538(20)31418-6/fulltext

Ariceta G, . The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int [published online ahead of print December 8, 2020]. doi: 10.1016/j.kint.2020.10.046; https://www.kidney-international.org/article/S0085-2538(20)31418-6/fulltext)| false
• Search Google Scholar
• Export Citation

Jayne DRW, et al.. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 2017; 28:2756–2767. doi: 10.1681/ASN.2016111179

• Crossref
Jayne DRW, . Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 2017; 28:2756–2767. doi: 10.1681/ASN.201611117910.1681/ASN.2016111179)| false
• Search Google Scholar
• Export Citation

Jayne DRW, et al.. ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 2021; 384:599–609. doi: 10.1056/NEJMoa2023386

• Crossref
Jayne DRW, . ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 2021; 384:599–609. doi: 10.1056/NEJMoa202338610.1056/NEJMoa2023386)| false
• Search Google Scholar
• Export Citation

Merkel PA, et al.. Evaluation of the safety and efficacy of avacopan, a C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated concomitantly with rituximab or cyclophosphamide/azathioprine: Protocol for a randomized, double-blind, active-controlled, phase 3 trial. JMIR Res Protoc 2020; 9:e16664. doi: 10.2196/16664

Merkel PA, . Evaluation of the safety and efficacy of avacopan, a C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated concomitantly with rituximab or cyclophosphamide/azathioprine: Protocol for a randomized, double-blind, active-controlled, phase 3 trial. JMIR Res Protoc 2020; 9:e16664. doi: 10.2196/16664)| false
• Search Google Scholar
• Export Citation